121 related articles for article (PubMed ID: 28314304)
1. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
Lawson BO; Khong HT
Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
[TBL] [Abstract][Full Text] [Related]
2. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
5. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alph-2b (Sylatron) for melanoma.
Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
[No Abstract] [Full Text] [Related]
12. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
[TBL] [Abstract][Full Text] [Related]
14. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
[No Abstract] [Full Text] [Related]
15. Allergic sensitization to pegylated interferon-α results in drug eruptions.
Meller S; Gerber PA; Kislat A; Hevezi P; Göbel T; Wiesner U; Kellermann S; Bünemann E; Zlotnik A; Häussinger D; Erhardt A; Homey B
Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
[TBL] [Abstract][Full Text] [Related]
16. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
17. Thyrotoxicosis with pegylated interferon alfa-2b.
Lowndes SA; Asher R; Middleton MR
Arch Dermatol; 2010 Nov; 146(11):1273-5. PubMed ID: 21079065
[TBL] [Abstract][Full Text] [Related]
18. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
Tarhini AA; Kirkwood JM
J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298
[No Abstract] [Full Text] [Related]
19. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
